Zoll Medical said today that it has acquired Respicardia and its neurostimulation tech for treating sleep apnea.
The financial terms of the deal were not disclosed.
Respicardia makes implantable neurostimulators to treat moderate to severe central sleep apnea (CSA). The system is FDA approved to treat severe CSA in adult patients with reduced cardiac function.
“Zoll and Respicardia both develop innovative therapies for conditions with large unmet clinical needs, and we share a deep commitment to improving patient outcomes,” Zoll Medical CEO Jon Rennert said in a news release. “With this acquisition, Zoll will combine its expertise in cardiac and respiratory care with Respicardia’s novel Remedē System to make a meaningful difference in the health and quality of life for many patients.”
A cardiac electrophysiologist implants Respicardia’s system during a minimally invasive outpatient procedure. It delivers electrical pulses to one of the phrenic nerves to sent signals to the diaphragm to restore a more normal breathing pattern during sleep.
“Respicardia is excited to be joining the Zoll family,” Respicardia CEO Peter Sommerness said. “As an innovator of safe and effective therapies that address the unmet needs of respiratory and cardiovascular patients, we see tremendous potential ahead with the support of Zoll’s strong brand and global reach.”
Through the deal, Respicardia’s global workforce will join Zoll and Respicardia’s current headquarters in Minnetonka, Minn. will remain.